Investor Presentaiton
Segment operating profit
(Excludes shared/non-allocated costs)
Chronic Care
Ostomy and Continence Care
59
59
58
58
57
Interventional Urology
Wound & Skin Care
Segment Operating Profit DKKm
Segment Operating Profit Margin (%)
Voice & Respiratory Care
2,357
2,397
2,500
2,456
31
35
37
36
35
40
42
222
2,375
38
39
37
31
E
239
244
235
289
291
222
266
261
249
175
Q2 21/22 Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23
57
58
59
59
57
9,586
8,774
8,318
7,798
Q2 21/22 Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23
Q2 21/22 Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23
41
39
39
40
40
37
38
36
35
35
1,029
1,089
914
941
4,831
818
860
728
654
479
I
32
32
33
34
A
148
156
162
143
92
Q2 21/22 Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23
32
32
33
540
•
383
318
FY 18/19 FY 19/20 FY 20/21 FY 21/22 YTD 22/23
FY 18/19 FY 19/20 FY 20/21 FY 21/22 YTD 22/23
FY 18/19 FY 19/20 FY 20/21 FY 21/22 YTD 22/23
FY 21/22 YTD 22/23
•
•
Voice & Respiratory Care is
Coloplast's new business
area, added with the
acquisition of Atos Medical.
FY 21/22 includes eight
months of impact.
Segment operating profit
for Voice & Respiratory
Care is excluding PPA
amortisation expenditures.
R&D costs for Interventional Urology and Voice and Respiratory Care are included in the segment operating profit/loss for the respective segments, while R&D costs for Chronic Care and Wound and Skin Care are shared between functions and
included under shared/non-allocated costs.
Financial items and income tax are not allocated to operating segments.
60
ColoplastView entire presentation